50 Northern Avenue
Boston , MA 02210
Boston , MA 02210
News
-
Vertex Pharmaceuticals Inc. dropped 0.4% to $467.98 after the biotech company posted lower income in the fourth quarter ending in December.
Revenue increased to $2.91 billion from $2.52 billion, net income dropped to $913.0 million from $968.8 million, and earnings per diluted share fell to $3.50 from $3.71 a year ago.
Revenue growth was primarily driven by the continued performance of TRIKAFTA/KAFTRIO, a prescription medicine used for cystic fibrosis treatment.
For fiscal 2025, the company estimated revenue between $11.75 billion and $12.0 billion, compar More
Feb 11, 2025 -
Vertex Pharmaceuticals edged up 0.6% to $400.0 after the company agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, or about $65 per share.
Alpine Immune soared 36% to $64.21.
Apr 11, 2024
Executive/
Director
Links
Price
- Last Close
-
$ 406.86
$ +1.05 0.26 %
Jan 3, 2025
- 52-Week High/Low
- $504.99 - $343
- YTD
- 1%
- Trading Volume
- 43,316
- Market Cap Full
- $ 104.8B
- Shares Outstanding
-
257.7M
Oct 31, 2023
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | -36.8% | 48.4% | 8.8% | 11% | -5% | -9.1% | 19.5% | 9.1% | 2.8% | 1% |
| Q2 | 8.2% | 17.9% | 8.7% | -2.1% | 4% | -6.2% | 7.4% | 11.7% | 12.4% | - |
| Q3 | 1.4% | 18% | 13.6% | -6.4% | 8% | -10% | 2.8% | -1.2% | -0.1% | - |
| Q4 | -15.5% | -1.6% | -13.5% | 28.3% | -13.2% | 21.1% | -0.3% | 17% | -22.1% | - |
| J | F | M | A | M | J | J | A | S | O | N | D | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 1% | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | 6.5% | -2.9% | -0.6% | -5.7% | 15.7% | 3.5% | 4.4% | -0.1% | - | - | - | -13.8% |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6% | -41% | 103% | 11% | 31% | 9% | -7% | 32% | 41% | -1% | 1% |
Earnings
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Q1 | 0.13 | 0.13 | 0.81 | 1.03 | 2.29 | 2.49 | 2.96 | 2.69 |
| Q2 | 0.01 | 0.10 | 0.8 | 1.03 | 3.18 | 0.26 | 3.13 | 3.52 |
| Q3 | 0.09 | 0.24 | 0.5 | 0.22 | 2.53 | 3.28 | 3.59 | 3.97 |
| Q4 | 0.13 | 0.32 | 5.98 | 2.23 | 2.29 | 2.98 | 3.14 | - |
| A | 0.4 | 0.8 | 8.1 | 4.5 | 10.3 | 9 | 12.8 | 10.18 |
Annual Returns
52 Week
High/Low
Annual
Earnings
Chart
Trading Volume
Outstanding Shares
(In Millions) +
Jan 16, 2024
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Mar | - | 255.7 | 259.3 | 260 | 254.6 | 257.1 |
| Jun | 254.8 | 256.1 | 259.3 | 258.9 | 255.8 | 257.6 |
| Sep | 255.6 | 257 | 260.5 | 259.4 | 256.5 | 258.1 |
| Dec | 255.6 | 257.1 | 260 | 254.3 | 256.7 | 257.7 |
SEC Filings
Financial Ratios
| 2022 | 2021 | 2020 | 2019 | 2018 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Management | ||||||||||||||||||
| Inventory / Stock Turnover | 2.3 | 2.6 | 2.6 | 3.3 | 3.3 | |||||||||||||
| Fixed Asset Turnover | 5.5 | 6.3 | 6.2 | 4.6 | 3.6 | |||||||||||||
| Total Asset Turnover | 0.5 | 0.6 | 0.5 | 0.5 | 0.5 | |||||||||||||
| Leverage | ||||||||||||||||||
| Debt Ratio | - | - | - | - | - | |||||||||||||
| Debt – Equity Ratio | - | - | - | - | - | |||||||||||||
| Interest Coverage | 4.4 | 6.3 | 19.8 | 57.1 | -0.4 | |||||||||||||
| Equity multiplier | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | |||||||||||||